Table 3 Asymmetric dimethylarginine (ADMA), homocysteine and carotid intima media thickness (CIMT) among the studied groups.
Biomarkers | Mean ± SD | ANOVA test and P value | Post hoc P value |
|---|---|---|---|
ADMA (μmol/l) | P1 < 0.001** | ||
Valproate-treated patients | 4.40 ± 0.75 | Test = 630.41 | P2 < 0.001** |
Levatiracetam-treated patients | 5.56 ± 0.61 | P value < 0.001** | P3 < 0.001** |
Multidrug-treated patients | 5.78 ± 0.62 | P4 = 0.06 | |
Controls | 1.27 ± 0.35 | P5 < 0.001** | |
P6 < 0.001** | |||
Homocysteine (μmol/l) | P1 = 0.28 | ||
Valproate-treated patients | 9.2 ± 1.7 | Test = 32.01 | P2 = 0.002* |
Levatiracetam-treated patients | 8.7 ± 2.1 | P value < 0.001** | P3 < 0.001** |
Multidrug-treated patients | 10.5 ± 3.3 | P4 < 0.001** | |
Controls | 6.4 ± 1.2 | P5 < 0.001** | |
P6 < 0.001** | |||
CIMT (mm) | P1 < 0.001** | ||
Valproate-treated patients | 0.33 ± 0.02 | Test = 42.88 | P2 < 0.001** |
Levatiracetam-treated patients | 0.32 ± 0.01 | P value < 0.001** | P3 < 0.001** |
Multidrug-treated patients | 0.35 ± 0.02 | P4 < 0.001** | |
Controls | 0.31 ± 0.02 | P5 = 0.09 | |
P6 < 0.001** |
